Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALKDiletta Fontana, Luca Mologni|Cancer Medicine|2015Cited by 88
Inhibition of RET tyrosine kinase by SU5416Luca Mologni, Carlo Gambacorti‐Passerini|Journal of Molecular Endocrinology|2006Cited by 54
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922Luca Mologni, Carlo Gambacorti‐Passerini|Oncotarget|2015Cited by 33
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphomaSara Redaelli, Luca Mologni|Oncotarget|2016Cited by 28
The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K InhibitionLuca Mologni, Carlo Gambacorti‐Passerini|Journal of Cancer|2017Cited by 13